{"eventGroups":[{"deathsNumAffected":2,"deathsNumAtRisk":21,"description":"Patients received 7 mg of MEDI0457 intramuscularly (weeks 1, 3, 7, 12, and every 8 weeks thereafter) and durvalumab 1500 mg intravenously every 4 weeks starting at week 4.","id":"EG000","otherNumAffected":21,"otherNumAtRisk":21,"seriousNumAffected":1,"seriousNumAtRisk":21,"title":"Treatment Group"}],"frequencyThreshold":"1","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":21}],"term":"Abdominal pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":21}],"term":"Alanine aminotransferase - increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":21}],"term":"Alkaline phosphatase - increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Anorexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":21}],"term":"Anxiety"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Arthralgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Arthritis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Ascites"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":21}],"term":"Aspartate aminotransferase - increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":21}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":21}],"term":"CPK increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Cholecystitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Cough"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Creatinine increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Dizziness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Dry mouth"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Dyspnea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Eosinophilia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":21}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Hyperglycemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":21}],"term":"Hyperthyroidism"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":21}],"term":"Hypokalemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":21}],"term":"Hyponatremia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":21}],"term":"Hypothyroidism"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":21}],"term":"Injection site reaction"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":21}],"term":"Lipase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":21}],"term":"Lymphopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Mucositis oral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":21}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":21}],"term":"Pain in extremity"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":21}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":21}],"term":"Rash maculo-papular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":21}],"term":"Serum amylase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Sinus bradycardia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Vomiting"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.3)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21}],"term":"Lipase increased"}],"timeFrame":"From the first dose through 30 days after the last dose of study medication, up to 2 years"}